AQR: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: AQR

NCBI ID: G9716

Content of Review Report on AQR Target / Biomarker

AQR

AQR: A Potential Drug Target and Biomarker for Neurological Disorders

AQR (FSAP164) is a protein that is expressed in the brain and is known for its role in the regulation of cell death. It is a potential drug target (or biomarker) for the treatment of various neurological disorders, including Alzheimer's disease.

The protein AQR is composed of 216 amino acids and has a calculated molecular weight of 23.9 kDa. It is expressed in the brain and is found in various tissues, including the brain, heart, and liver. It is involved in the regulation of cell death, which is a crucial process in the development and progression of many neurological disorders.

One of the most promising aspects of AQR is its potential as a drug target. The protein is known to interact with a variety of molecules, including the protein Bcl-2. Bcl-2 is a protein that is known to play a role in the regulation of cell death, and it is a potential drug target for many neurological disorders.

AQR has been shown to be involved in the regulation of cell death in various organisms, including mammals. For example, studies have shown that AQR is involved in the regulation of cell death in the brain, and that it plays a role in the development and progression of neurodegenerative diseases.

In addition to its potential as a drug target, AQR is also a potential biomarker for the diagnosis and progression of many neurological disorders. The protein is known to be expressed in the brain, and its levels have been shown to be decreased in individuals with certain neurological disorders. This suggests that AQR may be a useful biomarker for the diagnosis and progression of these disorders.

AQR is also a potential target for small molecules, such as drugs, to treat various neurological disorders. For example, studies have shown that AQR is involved in the regulation of cell death in neurodegenerative diseases, and that small molecules have been shown to interact with AQR. This suggests that AQR may be a useful target for the development of new treatments for these disorders.

In conclusion, AQR is a protein that is expressed in the brain and is involved in the regulation of cell death. Its potential as a drug target and biomarker make it an attractive target for the development of new treatments for various neurological disorders. Further research is needed to fully understand the role of AQR in the regulation of cell death and its potential as a drug and biomarker.

Protein Name: Aquarius Intron-binding Spliceosomal Factor

Functions: Involved in pre-mRNA splicing as component of the spliceosome (PubMed:11991638, PubMed:25599396, PubMed:28502770, PubMed:28076346). Intron-binding spliceosomal protein required to link pre-mRNA splicing and snoRNP (small nucleolar ribonucleoprotein) biogenesis (PubMed:16949364). Plays a key role in position-dependent assembly of intron-encoded box C/D small snoRNP, splicing being required for snoRNP assembly (PubMed:16949364). May act by helping the folding of the snoRNA sequence. Binds to intron of pre-mRNAs in a sequence-independent manner, contacting the region between snoRNA and the branchpoint of introns (40 nucleotides upstream of the branchpoint) during the late stages of splicing (PubMed:16949364). Has ATP-dependent RNA helicase activity and can unwind double-stranded RNA molecules with a 3' overhang (in vitro) (PubMed:25599396)

The "AQR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AQR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets